Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November.
The drug’s manufacturer, Novartis, said Sept. 29 it plans to launch a direct-to-patient platform on Nov. 1 for cash-paying U.S. patients. For a four-week supply, Cosentyx’s list price is $7,936 for a self-injection package and $4,401 per intravenous infusion, according to Novartis.
Cosentyx (secukinumab) is an FDA-approved biologic to treat six immune-mediated inflammatory diseases, including plaque psoriasis and psoriatic arthritis.
In 2024, hospitals, clinics, pharmacies and other healthcare facilities spent $7.7 billion on the medication, making it the 16th most expensive drug in healthcare.
Several other drugmakers have recently launched direct-to-consumer portals and other platforms that offer discounts to cash-paying patients, including Pfizer, Eli Lilly and Novo Nordisk.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
